Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies
- Users also seek instruments that provide a greater range of colors and rapid analysis of multiple samples, finds Frost & Sullivan
MOUNTAIN VIEW, California, June 3, 2015 /PRNewswire/ -- Flow cytometry remains an indispensable part of the healthcare sector around the globe and keeping track of wide-ranging consumer needs is fundamental for success in this competitive market. In particular, ensuring user-friendliness, fluorescence capabilities, specialized research and clinical applications and detection sensitivity are the most important factors influencing end-user purchase decisions and help solution providers widen their consumer base.
Logo - http://photos.prnewswire.com/prnh/20150601/219949LOGO
New analysis from Frost & Sullivan, 2015 Global Survey on Flow Cytometry Adoption Trends (https://www.frost.com/nf60), finds core facilities that cater to hospitals, allocate the maximum budget for flow cytometry purchases. Academic and hospital laboratories account for the highest percentage of laboratory budgets between $71,000 to $1,000,000 USD. The study surveyed decision-makers working in laboratories, hospitals, academic institutions and government facilities.
For complimentary access to more information on this research, please visit: http://bit.ly/1JwKtPF.
"Researchers demand instruments with multiple light sources and different wavelengths in order to excite a greater range of colors and facilitate the rapid analysis of multiple samples," said Frost & Sullivan Life Sciences Senior Industry Analyst Divyaa Ravishankar. "The increasing use of solid-state lasers, semiconductor lasers and mercury lamps, in addition to traditionally preferred gas lasers, as light sources has propelled fluorescence as an important criterion for consumers."
Consumer preferences shaping equipment adoption are:
- Scientists looking for flow cytometry instrumentation that allows complementary approaches for diverse applications
- Immunophenotyping, the most popular research application for flow cytometry, closely followed by cell proliferation and cancer applications
- Strong brands including: BD Biosciences (www.bdbiosciences.com), Beckman Coulter (www.beckmancoulter.com), and EMD Millipore (www.emdmillipore.com)
- Sony Biotechnology (www.sonybiotechnology.com), who is climbing up the ladder as a preferred brand
"Polymerase chain reaction and microarray technologies will continue to be predominantly used along with flow cytometry," observed Ravishankar. "As next-generation sequencing catches up, partnerships between flow instrument vendors and sequencing vendors will grow, quickening the deployment of automated workflows and broadening the application scope for flow cytometry."
2015 Global Survey on Flow Cytometry Adoption Trends is a Customer Research study that is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. The study analyzes the utilization of flow cytometry instruments and reagents, covering factors that drive the selection of flow cytometers, predominantly used applications for flow cytometers, preferred brands and why, complementary technologies used along with flow cytometry, unmet needs and challenges and laboratory budgets for new equipment and reagent purchases.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
2015 Global Survey on Flow Cytometry Adoption Trends
NF60-52
Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: kayla.belcher@frost.com
Twitter: @Frost_Sullivan
Facebook: FrostandSullivan
Linkedin: http://linkd.in/1cLg0jY
Share this article